{"Clinical Trial ID": "NCT00244881", "Intervention": ["INTERVENTION 1:", "Treatment (Cediranib Maleate)", "Patients receive AZD2171 orally once daily for 42 days. Courses are repeated every 42 days in the absence of disease progression or unacceptable toxicity."], "Eligibility": ["Incorporation criteria:", "Patients should have histologically or cytologically confirmed breast cancer at stage IV, including:", "\"The malignant and unspecified breast neoplasms (including nipples), \"The breast neoplasms and malignant nipples\", \"The breast cancer stage IV\", \"10006202\"", "\"Malignant and unspecified breast neoplasms (including nipple), \"Mammary neoplasms and malignant nipples\", \"Recurring breast cancer\", \"10006198\"", "\"Breast malignant and unspecified neoplasms (including nipples), \"Breast and malignant neoplasms\", \"Inflammatory carcinoma of breast stage IV\",\"10021979\"", "Patients should have a measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (the longest diameter to record) as >= 20 mm with conventional techniques or >= 10 mm with spiral scan", "Patients should have refractory breast cancer, defined as a clear clinical tumour progression on the most recent treatment either by hormonal therapy, chemotherapy and/or trastuzumab; patients with up to 3 previous chemotherapy regimens and a number of biological regimens (hormonal, trastuzumab) for metastatic breast cancer will be eligible.", "\u2022 Life expectancy greater than 3 months, assessed by the patient's main oncologist", "Absolute neutrophil count > 1,500/mcL", "Platelets > 100 000/mcL", "Hemoglobin >= 8 g/dL", "Prothrombin time < upper institutional limit of normal (ULN)", "Total bilirubin = < 1.5 x ULN", "AST(SGOT)/ALT(SGPT) = < 2.5 \u00d7 LSN", "\u2022 Creatinine within normal institutional limits", "Urinalysis with proteinuria < 1+", "- Troponin T or I within normal institutional limits", "- LVEF >= 45%, as evaluated by echocardiogram or nuclear medicine study, within 30 days of initiation of protocol-based treatment", "At present, the potential for AZD2171 for clinically significant drug interactions involving CYP isozymes is unknown; however, rat studies of the agent indicate possible suppression of CYP1A that may be of biological importance; the eligibility of patients receiving drugs or substances known to affect or may affect the activity or PK of AZD2171 will be determined after their case has been examined by the Principal Investigator.", "AZD2171 has been shown to terminate fetal development in rats, as planned for a VEGF-dependent process; for this reason, women of childbearing potential must undergo a negative pregnancy test prior to entry into the study; women of childbearing potential and men must agree to use adequate contraception (hormonal method or birth control barrier; abstinence) prior to entry into the study and for the duration of the study; if a woman is pregnant or suspects that she is pregnant while participating in the study, she must immediately inform her attending physician.", "No therapeutic anticoagulation; use of low-dose warfarin (1-2 mg/day), intermittent doses of TPA (2 mg x 1) or heparin puffs for prophylax against central venous catheter clots is acceptable", "Capacity to understand and willingness to sign a written informed consent document", "- Exclusion criteria:", "* Patients who have undergone chemotherapy, radiotherapy or major surgery within 4 weeks (6 weeks for nitrosourea or mitomycin C) prior to their entry into the study or those who have not recovered adverse reactions from agents administered more than 4 weeks earlier", "Patients may not receive any other research officers or have participated in an experimental trial within the last 30 days.", "Patients may not have been previously treated with anti-angiogenesis", "\\Patients cannot receive any drugs that could significantly affect renal function (e.g. vancomycin, amphotericin, pentamidine); these drugs will also not be allowed after the study has started.", "Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurological dysfunction that would confuse the evaluation of neurological and other adverse events; a head CT or MRI should be performed at baseline.", "History of allergic reactions attributed to compounds of chemical or biological composition similar to AZD2171", "Any contraindications or impediments to the use of oral medicines", "EKG abnormalities of known clinical importance, such as the prolonged QT interval (mean QTc > 470 msec, with Bazett correction, in the screening electrocardiogram or family long QT syndrome history); EKG is required for entry into the study", "\u2022 Uncontrolled intercurrent disease including, but not limited to, hypertension, continuous or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia or psychiatric/social conditions that would limit compliance with study requirements", "Because AZD2171 is a VEGF inhibitor with known abortive effects, pregnant women are excluded from this study; because there is an unknown but potential risk of adverse effects in infants who are breastfed secondary to the mother's treatment with AZD2171, breastfeeding should be discontinued if the mother is treated with AZD2171.", "Patients who are HIV-positive on combination antiretroviral therapy are not eligible because of the potential for pharmacokinetic interactions with AZD2171; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.", "In the AZD2171 studies (see Appendix J for a list of these agents), patients with an increased risk of compromised EVF requiring the simultaneous use of proarrhythmic drugs or biologics are prohibited.", "Patients with a New York Heart Association Classification III or IV are excluded (NOTE: Class II patients are eligible if they are controlled by drugs and stable with increased surveillance)"], "Results": ["Performance measures:", "Fraction of patients with increased levels of circulating endothelial cells", "A 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will not exceed 40% (e.g., if 13 out of 26 patients respond, the CI is 30% to 70%).", "Delay: After 3 weeks of treatment", "Results 1:", "Title of the arm/group: Treatment (Cediranib Maleate)", "- Arm/group description: Patients receive AZD2171 orally once daily for 42 days. Courses are repeated every 42 days in the absence of disease progression or unacceptable toxicity.", "Total number of participants analysed: 26", "Type of measurement: Number", "Unit of measure: percentage of participants 30"], "Adverse Events": ["Undesirable Events 1:", "Total: 7/26 (26.92 per cent)", "Left ventricular systolic function 1/26 (3.85%)", "Hypertension 1/26 (3.85 per cent)", "1/26 (3.85 per cent)", "Esophagitis 1/26 (3.85 per cent)", "\u2022 Vesicle abnormality 1/26 (3.85 per cent)", "Diarrhoea 1/26 (3.85 per cent)", "Dyspnoea 1/26 (3.85 per cent)"]}